Kellum John A, Devarajan Prasad
Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, 604, Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA.
Biomark Med. 2014;8(10):1239-45. doi: 10.2217/bmm.14.82.
Biomarkers for acute kidney injury have numerous potential roles to play both at the bedside and in the design and conduct of clinical trials. Given the heterogeneous nature of this disease and the difficulty, so far, in developing effective therapies, a strategy that deploys all of our available tools in the treatment and in study of treatments would seem prudent. In this review, we discuss how biomarkers will change the way we do we take care of patients with and do clinical trials in acute kidney injury and why, in fact, biomarkers are necessary.
急性肾损伤的生物标志物在床边以及临床试验的设计和实施中都有众多潜在作用。鉴于这种疾病的异质性以及迄今为止开发有效疗法的困难，在治疗和治疗研究中部署我们所有可用工具的策略似乎是明智的。在这篇综述中，我们讨论生物标志物将如何改变我们照顾急性肾损伤患者以及进行急性肾损伤临床试验的方式，以及实际上为什么生物标志物是必要的。
